Gary Lyman, MD, MPH, an oncologist and hematologist, explains that biosimilar substitution in the absence of interchangeability designations is widespread and not without clinical merit.
Gary Lyman, MD, MPH, is an oncologist, hematologist, and public health researcher who has long been an advocate for biosimilars. He has also developed guidelines in support of using biosimilars in the oncology space.
Transcript:
Is the interchangeable designation actually meaningful and necessary?
Lyman: So, as I often mention, the United States is the only country that has a designation of interchangeability. Globally, this would have very little impact in meaning. I think the reason is that interchanging [of these agents] is driven by the originator's safety and efficacy data and acceptance by the professional oncology organizations. Just showing that you can switch from one to the other, once you've already said that the agent is safe and effective as the originator, I think there's been very little question raised. There still is a little bit of hesitancy, in general, about changing products in the middle of a course of treatment. So, if a patient has started adjuvant therapy with a biosimilar and has been told that they have to use a different one to complete their therapy, it just doesn't sit real well with clinicians. Why should they be forced to switch a product that seems to be working fine and the patient is tolerating well just because it's a little less expensive or they're being told [to do so] by their institution?
So, there is some pushback, and with regard to that, but in general, interchanging of these agents is already taking place. No biosimilar has been removed from the marketplace, either in Europe or in the United States, even globally, that I'm aware of, because of concerns over adverse events or loss of efficacy by changing from one agent to the other. So, and as I've said, many times, even the reference product that we prescribe of a biologic, the originator drug, is not the same drug today as it was 20 years ago. So, it's, in a sense, a biosimilar of itself sitting on the shelf right now. Saying that we can't switch or shouldn't switch because of cost or regional concerns just doesn't hold up very strongly in my mind. I think that pushback on this issue, while I understand it and the gut feeling of why change? When something's working don't fix it. I'm not concerned about the safety and efficacy of doing that.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.